Search Results - "Negrier, Claude"

The Hemophilia Gene Therapy Patient Journey: Questions and Answers for Shared Decision-Making.

Authors: Wang, Michael Negrier, Claude Driessler, Frank et al.

Source: Patient Preference & Adherence. Jun2022, Vol. 16, p1439-1447. 9p.

The effect of emicizumab prophylaxis on health‐related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study.

Authors: Oldenburg, Johannes Negrier, Claude Kessler, Craig et al.

Source: Haemophilia. Jan2019, Vol. 25 Issue 1, p33-44. 12p. 1 Diagram, 4 Charts, 6 Graphs.

Individually Tailored Prophylaxis in Patients with Severe Hemophilia.

Authors: Dargaud, Yesim Negrier, Claude

Source: Journal of Coagulation Disorders. 2010, Vol. 2 Issue 2, p11-17. 7p. 2 Graphs.

Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor EX with albumin (rIX-FP) in hemophilia B patients.

Authors: Santagostino, Elena Negrier, Claude Klamroth, Robert et al.

Source: Blood. 9/20/2012, Vol. 120 Issue 12, p2405-2411. 7p.

Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B.

Authors: Negrier, Claude Knobe, Karin Tiede, Andreas et al.

Source: Blood. 9/8/2011, Vol. 118 Issue 10, p2695-2701. 7p.

Coagulation factor concentrates: past, present, and future.

Authors: Key, Nigel S. Negrier, Claude

Source: Lancet. 8/4/2007, Vol. 370 Issue 9585, p439-448. 10p. 1 Diagram, 2 Charts.

Subjects: Blood coagulation factors, Blood coagulation disorders, Hemophilia treatment, Blood transfusion, Blood coagulation, Prions, HIV infection transmission, Hepatitis C transmission, Biotechnology, Bioengineering

Illegitimate transcription: its use for studying genetic abnormalities in lymphoblastoid cells from patients with Glanzmann thrombasthenia.

Authors: Negrier, Claude Vinciguerra, Christine Attali, Olivier et al.

Source: British Journal of Haematology. Jan1998, Vol. 100 Issue 1, p33-39. 7p. 2 Black and White Photographs, 2 Diagrams, 1 Chart.

Potential limits of AAV‐based gene therapy with the use of new transgenes expressing factor IX fusion proteins.

Authors: Le Quellec, Sandra Enjolras, Nathalie Negrier, Claude et al.

Source: Haemophilia. Jan2019, Vol. 25 Issue 1, pe11-e18. 8p. 3 Graphs.

florio HAEMO—A Digital Medical Device for Monitoring of Treatment, Symptoms and Physical Activities for People Living With Haemophilia.

Authors: Königs, Christoph Astermark, Jan Blatny, Jan et al.

Source: Haemophilia. Mar2026, Vol. 32 Issue 2, p438-446. 9p.

A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one‐stage clotting and chromogenic substrate assays at clinical haemostasis laboratories.

Authors: Pipe, Steven Sadeghi‐Khomami, Ali Konkle, Barbara A. et al.

Source: Haemophilia. Jan2024, Vol. 30 Issue 1, p214-223. 10p.

A Need for Evidence-Based Answers to Coagulation and Pharmacogenetics.

Authors: Shuman, Jill Negrier, Claude Paré, Guillaume et al.

Source: MD Conference Express. Aug2015, Vol. 15 Issue 21, p24-25. 2p.

Occupational integration of adults with severe haemophilia (INTHEMO): A study based on the FranceCoag registry.

Authors: Nguyen, Ngoc Anh Thu Auquier, Pascal Beltran Anzola, Any et al.

Source: Haemophilia. Nov2022, Vol. 28 Issue 6, p962-976. 15p. 2 Diagrams, 8 Charts.

Multiple criteria decision analysis for therapeutic innovations in a hemophilia care center: A pilot study of the organizational impact of innovation in hemophilia care management.

Authors: Beny, Karen Dubromel, Amélie du Sartz de Vigneulles, Benjamin et al.

Source: PLoS ONE. 9/9/2022, Vol. 17 Issue 9, p1-14. 14p.

Report of surgeries, their outcome and the thrombin generation assay in patients with Factor XI deficiency: A retrospective single‐centre study.

Authors: Désage, Stéphanie Dargaud, Yesim Meunier, Sandrine et al.

Source: Haemophilia. Mar2022, Vol. 28 Issue 2, p301-307. 7p. 3 Charts, 1 Graph.

Patients' Perception of the Impact of Innovation on Hemophilia Care Management Organization: A Qualitative Study Protocol (INNOVHEMO Study).

Authors: Beny, Karen Vigneulles, Benjamin du Sartz de Chamouard, Valerie et al.

Source: Patient Preference & Adherence. Aug2021, Vol. 15, p1807-1815. 9p.

Confirmed long‐term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A: final results of the PROTECT VIII extension study.

Authors: Reding, Mark T. Pabinger, Ingrid Holme, Pal Andre et al.

Source: Haemophilia. May2021, Vol. 27 Issue 3, pe347-e356. 10p. 1 Diagram, 4 Charts, 3 Graphs.

BAY 94‐9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results.

Authors: Lalezari, Shadan Reding, Mark T. Pabinger, Ingrid et al.

Source: Haemophilia. Nov2019, Vol. 25 Issue 6, p1011-1019. 9p. 1 Diagram, 2 Charts, 3 Graphs.

REACH: A programme for improving care in haemophilia.

Authors: Goga, Yasmin Boukari, Rachida Bensadok, Meriem et al.

Source: Haemophilia. May2019, Vol. 25 Issue 3, pe211-e215. 5p. 2 Charts.

Hypertension, haematuria and renal functioning in haemophilia - a cross-sectional study in Europe.

Authors: Holme, P. A. Combescure, C. Tait, R.C. et al.

Source: Haemophilia. Mar2016, Vol. 22 Issue 2, p248-255. 8p. 2 Black and White Photographs, 4 Charts.

Intraindividual thrombin generation measurement variability in healthy adults over a one year period

Authors: Dargaud, Yesim Francillon, Stephanie Negrier, Claude

Source: Thrombosis Research. Jun2009, Vol. 124 Issue 2, p237-238. 2p.